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Centre Hospitalier de l'Université de Montréal (CHUM); Canadian National TRANSPLANT Research Program Meeting donor management goals (DMGs) has been reported to decrease the incidence of delayed graft function (DGF) after kidney transplant, but whether this relationship is independent of cold machine perfusion is unclear. We aimed to determine whether meeting DMGs is associated with a reduced incidence of DGF, independent of the use of machine perfusion. We collected data on consecutive brain-dead donors and their KT recipients (KTRs) between June 2013 and December 2016 in 5 adult transplant centers. We evaluated whether DMGs were met at donor neurologic death (DND) and later time points. We defined a priori meeting optimal DMG as achieving ≥7 DMGs. Generalized estimating equations were used to predict DGF. Early achievement of DMGs was associated with a reduced risk of the development of DGF, independent of the use of machine perfusion.
K E Y W O R D S
clinical research/practice, critical care/intensive care management, delayed graft function (DGF), donation after brain death (DBD), donors and donation, kidney transplantation/ nephrology, organ procurement and allocation Meeting donor management goals (DMGs) could improve the rate of DGF by helping to preserve the donor's kidney function.
Different organizations have established prespecified DMGs to restore and stabilize physiologic functions. 21, 22 A recent study from the United States suggests that meeting several hemodynamic, respiratory, and metabolic goals in organ donors could reduce the incidence of DGF in KT recipients (KTRs). 4 However, this study did not take into account the use of machine perfusion.
Hence, our aims were to assess the efficacy and timeliness of meeting brain-dead DMGs in our population and to determine the impact of meeting DMGs at donor neurologic death (DND) on DGF, independent of the use of machine perfusion.
| MATERIAL S AND ME THODS

| Study design and population
We performed a retrospective cohort study of consecutive neuro- We included all adult organ donors for whom ≥1 kidney was transplanted. We excluded donation after circulatory determination of death, pediatric KTRs, patients with no follow-up data due to transfer outside the province, as well as combined organ transplant with dysfunction of the other organ.
We followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for observational studies. 23 The ethics committee of each institution approved the study (MP-32-2015-1132). Written consent was waived given the retrospective observational nature of the study. The study was performed in accordance with the 1964 Declaration of Helsinki and its later amendments.
| Data collection
The primary outcome was the occurrence of DGF, which was defined as the need for dialysis in the first posttransplant week. 4, 16, 17 The main independent variable of interest was meeting DMGs at DND. Treatment guidelines from our regional organ donor organization, Transplant-Québec 22 (Table S1) , were used to assess whether DMGs had been met at different time points (DND, after 12 hours and 24 hours after DND, and before organ procurement [OP]). We defined a priori meeting optimal DMG as achieving ≥7 DMGs 4 (Table S1 ).
Appropriate use of vasopressors was defined in Table S1 . 22 ECDs were defined as donor age >60 years or >50 years in the presence of 2 of the following: stroke as cause of death, serum creatinine >1.5 mg/dL (133 μmol/L), or history of hypertension.
We used chart review to collect data on kidney donors and re- 
| RE SULTS
The cohort included 122 deceased donors and their 214 KTRs We stratified achievement of DMGs by the DGF status of the 214
KTRs at the different time points. The results at DND are presented in Table 3 . Achievement of DMG at 12 hours, 24 hours, and at OP are presented in supplemental material (Tables S2-S4 Recipient characteristics and perioperative management are shown in Table 4 . In terms of immunosuppression, the vast majority of patients (87%) were receiving tacrolimus, mycophenolic acid, and prednisone. Median CIT was kept short at 12.7 (IQR 7.9-16.6) hours, and 55% of recipients received organs that were machine perfused.
Donor characteristics according to use or nonuse of machine perfusion are included in supplemental material (Table S5 ). There were no significant differences in donor characteristics between kidneys that received and those that did not receive machine perfusion.
Twenty-three percent of KTRs experienced DGF. Univariate and multivariate risk factors for DGF are presented in Table 5 . In multivariate analysis, ECDs were a risk factor for DGF (odds ratio CI 0.16-0.99; P = .04, respectively). We found that prolonged CIT was not associated with DGF, and there was no effect of meeting DMGs at later time points than at DND in the prevention of DGF.
Nevertheless, because there was an increase in DMGs over time and this could have had an effect on DGF, we repeated the analyses 
| D ISCUSS I ON
We found that the percentage of DMGs met modestly increased over time and that the achievement of optimal DMGs at DND was associated with a reduction in the incidence of DGF, independent of the use of machine perfusion and donor quality. We confirmed that the use of machine perfusion was protective for the development of DGF, while ECD status was associated with an increased risk of DGF. the number and quality of transplanted organs. 4, 21, 22 Our results suggest that early optimal DMGs could improve the rate of DGF. These results were also significant for hemodynamic DMGs only at DND.
Our findings should be considered in the context of prior research.
We found that the percentage of DMGs met was relatively low, being 25% at DND and 36% at OP. However, our percentages compare favorably with those from a previous study performed in the United States,
where DMGs were initially met in 14% of donors and in 38% prior to OP. 4 In our study, meeting DMGs at DND was associated with a 12% reduction in DGF, compared with a previous rate of 13%. 4 Importantly, covariates such as the use of machine perfusion, PRA, and dialysis vintage were not available in the previous study. 4 Despite varying practice patterns of OPO between countries, we replicated findings observed in the United
States showing that a combination of DMGs met lowered the incidence of DGF, 4 even after adjusting for additional well-established risk factors 16, 26 CIT, a well-known risk factor for DGF, was not an independent risk factor for DGF in our study. We hypothesized that this is due to the short CITs observed in the province of Quebec. Specific DMGs, such as body temperature or use of low-dose dopamine, have been associated with reduced rates of DGF. 9, 27 In our population, low-dose dopamine was rarely used and was not specifically recommended by our regional guidelines. This is in concordance with recommendations from the Society of Critical Care
Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations reporting insufficient evidence to preferentially recommend dopamine over other vasopressors. 28 One study on mild hypothermia showing a reduction in the risk of DGF was published after the initiation of this study and the publication of our regional donor guidelines. In our patient cohort, body temperatures were similar in patients with and without DGF but were in the normothermic range.
The timing of donor management seems to have clinical relevance.
We found that early optimal DMGs were associated with better outcomes, as shown by Malinoski et al 4 We confirmed that meeting DMGs Our study has several strengths. We performed a multicenter study that included the most important risk factors for DGF, such as CIT, ECD, and use of machine perfusion. We assessed DMGs at DND because our goal was to assess the association as early as possible to further refine donor and organ management. We also explored later time points in the process of donation to assess whether more sustained respect of DMGs could further improve the rate of DGF. We specifically assessed hemodynamic DMGs to further understand the relationship between hemodynamic status and kidney function.
Limitations to the current study include its limited sample size and observational design. As with any observational study, unmeasured confounding between donor and recipient characteristics and the development of DGF could have occurred. For example, traumatic events leading to donor death, or the inflammatory activation surrounding the initial brain insult and the subsequent brain death, could have been less severe in patients in whom DMGs were achieved.
The sample size precluded a thorough evaluation of potential effect modification between machine perfusion, optimal DMGs, and DGF.
Second, we have used regional treatment guidelines, which may limit the generalizability of our findings. In addition, there was a relatively high percentage of missing data for some of the hemodynamic DMGs, and we did not have access to continuous monitoring for hemodynamic DMGs, precluding more sophisticated analyses. Finally, the previously reported effect of low-dose dopamine as an adjunct antioxidant treatment or of donor hypothermia on DGF could not be explored due to very scarce data on these issues, owing to the DMGs of Transplant-Quebec.
In conclusion, this study confirms that meeting optimal DMGs early during donor management is associated with a decreased Coronary artery disease, n (%) 48 (22) 14 (29) 34 (21) .24
Peripheral artery disease, n (%) 32 (15) 9 (18) 23 (14) .45
Active smoking, n (%) 32 (15) 9 (18) 23 (14) .45
Cause of ESRD, n (% incidence of DGF in KTRs and that this relationship is independent of machine perfusion, donor quality, and dialysis vintage. Future prospective studies on long-term outcomes in terms of graft function will be needed to assess the full benefit of meeting DMGs. 
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